Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Improved response by co-targeting EGFR/EGFRvIII and Src family kinases in human cancer cells

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The effect of adenovirus-mediated gene expression of FHIT in small cell lung cancer cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
We hypothesized that co-targeting the epidermal growth factor receptor (EGFR) and Src with the EGFR inhibitor gefitinib and the Src inhibitor AZD0530 would increase growth inhibition and impede migration. Cells overexpressing EGFR were more sensitive to gefitinib than cells expressing mutated EGFR or normal levels of wild-type EGFR. Furthermore, cells with mutated EGFR responded to low doses of gefitinib with increased proliferation. AZD0530 was an effective inhibitor of proliferation and migration, irrespective of EGFR status. These results suggest that co-targeting EGFR and Src might be a valuable treatment approach for malignancies associated with altered expression of EGFR, EGFRvIII, and/or Src.
OriginalsprogEngelsk
TidsskriftCancer Investigation
Vol/bind27
Udgave nummer2
Sider (fra-til)178-83
Antal sider6
ISSN0735-7907
DOI
StatusUdgivet - 1 feb. 2009

ID: 31047978